| Budget Amount *help |
¥23,270,000 (Direct Cost: ¥17,900,000、Indirect Cost: ¥5,370,000)
Fiscal Year 2018: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2017: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000)
Fiscal Year 2016: ¥8,970,000 (Direct Cost: ¥6,900,000、Indirect Cost: ¥2,070,000)
Fiscal Year 2015: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
|
|---|
| Outline of Final Research Achievements |
Unlike coding mutations, extent of somatic mutations in non-coding regulatory regions remains largely unknown. In this study, we performed ChIP-sequencing analysis of lung cancer clinical tissue samples. Discovery of large number of somatic mutations in promoters and other regulatory regions indicates potential impact of non-coding mutations in cancer. ChIP-sequencing also identified allele-specific regulation of cancer-associated regulatory regions. Such information is highly useful to filter potential functional variants, and similar strategy could be applied to other clinical research including rare diseases. It is also important to develop method to utilize functional variants as diagnostic markers and as drug targets. Functional SNPs could be developed as a predictive marker for disease susceptibility, and somatic mutations could predict effect of drugs targeting certain transcriptional regulatory network.
|
